Last reviewed · How we verify

NCT06076759

Intrathecal Dexmedetomidine Versus Intrathecal Morphine Inpatients Undergoing Cardiac Valve Replacement Surgeries: Effect on Postoperative Pain and Diaphragmatic Function

Status unknown NA Last updated 8 October 2023
What this trial tests

NA trial testing Intrathecal morphine or dexmedetomidine in Cardiac Valve Disease in 40 participants. Status unknown.

Timeline
1 October 2023
Primary endpoint
1 October 2024
1 November 2024

Quick facts

Lead sponsorAssiut University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposesupportive care
Enrollment40
Start date1 October 2023
Primary completion1 October 2024
Estimated completion1 November 2024

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Adults 18 to 65, any sex, with Cardiac Valve Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

Comparison between the effects of intrathecal morphine versus intrathecal dexmedetomidine on analgesia and respiratory function, in open heart surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cardiac Valve Disease

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06076759.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing